Insight Molecular Diagnostics Inc. Ordinary Shares IMDX 深 滬
等待開盤 10-04 09:30:00 美东时间
3.35
+0.010
+0.30%
華盛通- 最 高3.57
- 今 開3.4018
- 成交量 2.27万股
- 最 低 3.30
- 昨 收 3.34
- 總市值 9587.60万
- 52周最高 4.75
- 市盈率 靜 --
- 換手率 0.08%
- 52周最低 1.922
- 委 比 99.98%
- 總股本 2861.97万
- 歷史最高 204.80
- 量 比 1.65
- 振 幅 8.08%
- 歷史最低 1.922
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Insight Molecular Diagnostics Extends Executive Employment Agreement
Insight Molecular Diagnostics ( ($IMDX) ) just unveiled an update. On September...
10-03 04:35
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD announced inducement grants of 88,324 restricted shares to five new non-executive employees outside its 2021 Equity Incentive Plan under the 2024 Inducement Plan. The grants vest over three years, with one-third vesting annually on the first, second, and third anniversaries, contingent on continued employment.
09-25 20:05
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando
Insight Molecular Diagnostics Inc. (iMDx) will present its GraftAssureIQ research-use-only test kit and discuss the clinical potential of its GraftAssure technology at two major conferences. At the IATDMCT annual meeting in Singapore, the company will host a symposium on September 24 to highlight how GraftAssureIQ can improve transplant rejection detection and treatment monitoring. In Orlando, iMDx and its partner Bio-Rad will present on October ...
09-24 11:05
Insight Molecular Diagnostics Approves Executive Salary Increases
Insight Molecular Diagnostics ( ($IMDX) ) just unveiled an announcement. On Sep...
09-20 04:36
Insight Molecular Diagnostics Enrolls Patients In Its Clinical Trial To Assess GraftAssureDx
iMDx's ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026NASHVILLE, Tenn., Sept. 08, 2025
09-08 19:07
Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database
- iMDx launches a new registry enrolling 5,000 kidney transplant patients across 25 centers to gather real-world data on its rejection assay. - The study aims to validate a "combined score" algorithm for donor-derived cell-free DNA (dd-cfDNA) and assess the Berlin Protocol for high-risk patients. - Over three years, approximately 50,000 samples will be collected. - The registry complements iMDx’s kit-based testing strategy and supports future in-...
09-08 11:15
IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants
iMDx宣布其针对器官移植排斥监测的GraftAssureDx临床试验已正式启动患者招募，目前已有10家顶尖移植中心参与，较之前增加了一倍。该试验旨在通过持续监测评估GraftAssureDx试剂盒在肾脏移植受体中的效果，计划于2025年底完成，并向FDA提交上市申请。预计2026年正式商业化，目标市场价值10亿美元。iMDx现有GraftAssureCore和GraftAssureIQ两款产品，正在积极拓展其分子诊断技术应用范围。
09-08 11:00
iMDx to Participate in NYC Investment Conferences September 8 - 11
Insight Molecular Diagnostics Inc. (iMDx) announced its participation in two upcoming investor conferences: the H.C. Wainwright 27th Annual Global Investment Conference on September 8-9, 2025, and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference (BIG9) on September 11, 2025. The company will present its strategy and meet with investors at both events. iMDx aims to enhance access to molecular diagnostic testing to improve pa...
08-26 20:05
Needham Reiterates Buy on Insight Molecular, Maintains $4.25 Price Target
Needham analyst Mike Matson reiterates Insight Molecular (NASDAQ:IMDX) with a Buy and maintains $4.25 price target.
08-18 17:59
OncoCyte GAAP EPS of -$0.30
OncoCyte press release (NASDAQ:IMDX): Q2 GAAP EPS of -$0.30. The company’s cash, cash equivalents, and restricted cash balance at the end of the second quarter was $26.0 million. More on OncoCyte On...
08-12 04:49
